Study Stopped
no acitve participants
Core-temperature Monitoring in Patients With PPROM
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The most common reason for preterm prelabor rupture of membrane (PPROM) is an ascendance of infection. Moreover PPROM is one of the main risk factors for chorioamnionitis. PPROM-related morbidity and mortality is higher in the neonate than in the mother, especially in case of intrauterine inflammation. Of note, the most common biomarkers like CRP and leucocytes are not specific for uterine infections and have not been proven useful in these particular cases. Studies in intensive care medicine could show that there is a possible correlation between onset of infection and body-core-temperature. The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. Twenty patients with verified PPROM between gestation week 22 and 27 should be included in this study. After gynecological and physical examination within verification of PPROM women will be informed and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix. The investigators aim to describe a possible correlation between core-temperature and common biomarkers in clinical use for the detection of chorioamnionitis in patients with PPROM to possibly assess the optimal time for delivery subsequently.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jan 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 23, 2014
CompletedFirst Posted
Study publicly available on registry
April 29, 2014
CompletedStudy Start
First participant enrolled
January 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2018
CompletedFebruary 26, 2021
November 1, 2016
7 months
April 23, 2014
February 23, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Body-core-temperature
The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day. As there is no change of common PPROM-therapy, only clinical standard parameters will lead to the termination of pregnancy. Directly before delivery the OvulaRing® will be removed and the sensor-data will be analyzed with a special software.
288 times a day from PPROM-verification until delivery
Secondary Outcomes (3)
CRP
once a day from hospitalization due to PPROM until delivery
Interleukine (IL-) 6
once a day from hospitalization due to PPROM until delivery
white blood cell count
once a day from hospitalization due to PPROM until delivery
Study Arms (1)
OvulaRing®
OTHERTwenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
Interventions
The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
Eligibility Criteria
You may qualify if:
- single pregnancy
- verified PPROM
- gestation week 22 to 27
- signed informed consent (ICF)
You may not qualify if:
- multiple pregnancy
- Patient's age under 18 years
- Allergy to epoxide resin or ethylene vinyl acetate (EVA)-Copolymer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Obstetrics and Gynecology, Medical University of Vienna
Vienna, 1090, Austria
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ljubomir Petricevic, Ass. Prof. M.D.
Medical University of Vienna
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Ass. Prof. Dr.
Study Record Dates
First Submitted
April 23, 2014
First Posted
April 29, 2014
Study Start
January 1, 2017
Primary Completion
August 1, 2017
Study Completion
January 1, 2018
Last Updated
February 26, 2021
Record last verified: 2016-11